Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study)

Cheng, V., Abdul-Aziz, M. H., Burrows, F., Buscher, H., Corley, A., Diehl, A., Jakob, S. M., Levkovich, B. J., Pellegrino, V., Que, Y. A., Reynolds, C., Rudham, S., Wallis, S. C., Welch, S. A., Zacharias, D., Roberts, J. A., Shekar, K., & Fraser, J. F. (2021). Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). International journal of Antimicrobial Agents,

Objectives: This study aimed to describe the population pharmacokinetics (PK) of cefepime during extracorporeal membrane oxygenation (ECMO) and through dosing simulations, identify a maximally effective and safe dosing strategy.

Previous
Previous

Implementation of the ABCDEF Bundle for Critically Ill ICU Patients During the COVID-19 Pandemic: A Multi-National 1-Day Point Prevalence Study

Next
Next

Development and characterization of a new swine model of invasive pneumococcal pneumonia